Swiss National Bank increased its position in shares of Chemours Company (The) (NYSE:CC) by 1.9% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 306,339 shares of the specialty chemicals company’s stock after buying an additional 5,600 shares during the quarter. Swiss National Bank owned about 0.17% of Chemours Company (The) worth $11,616,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in CC. Commerce Bank grew its stake in shares of Chemours Company (The) by 3.0% in the 2nd quarter. Commerce Bank now owns 7,158 shares of the specialty chemicals company’s stock valued at $272,000 after purchasing an additional 206 shares during the last quarter. Principal Financial Group Inc. grew its stake in shares of Chemours Company (The) by 5.3% in the 2nd quarter. Principal Financial Group Inc. now owns 794,592 shares of the specialty chemicals company’s stock valued at $30,131,000 after purchasing an additional 40,095 shares during the last quarter. 1060 Capital LLC purchased a new position in shares of Chemours Company (The) in the 2nd quarter valued at approximately $9,525,000. Cambridge Investment Research Advisors Inc. grew its stake in shares of Chemours Company (The) by 36.2% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 10,296 shares of the specialty chemicals company’s stock valued at $390,000 after purchasing an additional 2,738 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Chemours Company (The) by 11.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,367 shares of the specialty chemicals company’s stock valued at $279,000 after purchasing an additional 757 shares during the last quarter. Hedge funds and other institutional investors own 72.90% of the company’s stock.

Several research analysts have weighed in on CC shares. BidaskClub downgraded Chemours Company (The) from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. ValuEngine upgraded Chemours Company (The) from a “hold” rating to a “buy” rating in a research note on Friday, June 2nd. Citigroup Inc. upgraded Chemours Company (The) from a “neutral” rating to a “buy” rating and lifted their target price for the company from $43.00 to $45.00 in a research note on Wednesday, July 5th. Jefferies Group LLC reiterated a “buy” rating and issued a $48.00 target price on shares of Chemours Company (The) in a research note on Friday, June 16th. Finally, Zacks Investment Research upgraded Chemours Company (The) from a “hold” rating to a “strong-buy” rating and set a $51.00 target price on the stock in a research note on Friday, July 14th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Chemours Company (The) presently has an average rating of “Buy” and an average target price of $51.50.

COPYRIGHT VIOLATION NOTICE: “Swiss National Bank Grows Position in Chemours Company (The) (CC)” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/13/swiss-national-bank-grows-position-in-chemours-company-the-cc.html.

Shares of Chemours Company (NYSE:CC) opened at 49.99 on Wednesday. The firm has a market capitalization of $9.24 billion, a PE ratio of 32.72 and a beta of 3.64. Chemours Company has a 12-month low of $12.47 and a 12-month high of $51.59. The stock has a 50 day moving average price of $50.50 and a 200 day moving average price of $36.33.

Chemours Company (The) (NYSE:CC) last issued its quarterly earnings data on Wednesday, August 2nd. The specialty chemicals company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.02. Chemours Company (The) had a return on equity of 122.97% and a net margin of 4.96%. The business had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same period in the prior year, the company posted $0.27 EPS. The business’s revenue for the quarter was up 14.8% compared to the same quarter last year. Analysts predict that Chemours Company will post $3.51 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Thursday, August 17th will be issued a $0.03 dividend. This represents a $0.12 dividend on an annualized basis and a yield of 0.24%. The ex-dividend date is Tuesday, August 15th. Chemours Company (The)’s dividend payout ratio (DPR) is 8.11%.

In related news, insider E Bryan Snell sold 10,000 shares of the stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $46.24, for a total value of $462,400.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP David C. Shelton sold 13,337 shares of the stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $48.48, for a total value of $646,577.76. The disclosure for this sale can be found here. Insiders sold a total of 38,837 shares of company stock valued at $1,865,603 over the last three months. Corporate insiders own 1.14% of the company’s stock.

About Chemours Company (The)

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemours Company (The) (NYSE:CC).

Institutional Ownership by Quarter for Chemours Company (The) (NYSE:CC)

Receive News & Stock Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related stocks with our FREE daily email newsletter.